ArticleEcancermedicalscience2013
Breast cancer brain metastases: new directions in systemic therapy.
Article in Ecancermedicalscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Guideline
- ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.Future oncology (London, England) · 2019Trial
- Progressive Hypoxia Exacerbates Breast Cancer Metastasis by Paracrine Modulation of the Blood-brain Barrier Endothelium.Journal of molecular neuroscience : MN · 2026Article
- Article
- Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.Neuro-oncology · 2025Article
- Article
- Navigating the Blood-Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases.International journal of molecular sciences · 2023Review
- Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience.JCO global oncology · 2022Article
- Identification of Driver Genes and Interaction Networks Related to Brain Metastasis in Breast Cancer Patients.Disease markers · 2022Article
- Subtype switching in breast cancer brain metastases: a multicenter analysis.Neuro-oncology · 2020Article
- Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years.Breast (Edinburgh, Scotland) · 2020Article
- Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.Breast cancer research and treatment · 2020Article
- The management of elderly patients with brain metastases from breast cancer.Translational cancer research · 2020Review
- Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.Neuro-oncology · 2019Article
- Systemic therapy for brain metastases.Critical reviews in oncology/hematology · 2019Review
- The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity inClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Leptomeningeal Carcinomatosis: A Case Report of Metastatic Triple-negative Breast Adenocarcinoma.Cureus · 2019Article
- The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.Cell death & disease · 2018Article
- Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.JAMA oncology · 2018Article
- Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of patients with brain metastases from breast cancer continues to be a major clinical challenge. The standard initial therapeutic approach depends upon the size, location, and number of metastatic lesions and includes consideration of surgical resection, whole-brain radiotherapy, and stereotactic radiosurgery. As systemic therapies for control of extracranial disease improve, patients are surviving long enough to experience subsequent progression events in the brain. Therefore, there is an increasing need to identify both more effective initial treatments as well as to develop multiple lines of salvage treatments for patients with breast cancer brain metastases. This review summarises the clinical experience to date with respect to cytotoxic and targeted systemic therapies for the treatment of brain metastases, highlights ongoing and planned trials of novel approaches and identifies potential targets for future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.